title: Inhibitors of c-jun-N-terminal kinase (JNK).
abstract: Inhibitors of c-jun-N-Terminal Kinase (JNK) have many potential therapeutic indications ranging from neurodegenerative disease, to metabolic disorders, inflammation, cardiovascular disease, and cancer. This overview will highlight biological inhibitors such as JNK-interacting protein (JIP) as well as small molecule inhibitors from various structural classes including, aminopyrimidines and indazoles.
authors.affiliation: Department of Molecular Therapeutics and Drug Discovery, The Scripps Research Institute, 5353 Parkside Drive, Jupiter, FL 33458, USA. lograsso@scripps.edu
authors.forename: Philip
authors.initials: P
authors.lastname: LoGrasso
authors.forename: Theodore
authors.initials: T
authors.lastname: Kamenecka
mesh_terms: D000818:Animals; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology; D011804:Quinolines / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship
chemical_list: D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011804:Quinolines; C037219:quinoline; D048031:JNK Mitogen-Activated Protein Kinases; C023666:pyridine